Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology
tax legislation has now passed, and tariff rates get finalized
Pharmacological interventions for the prevention of antipsychotic-induced weight gain in people with schizophrenia: a cochrane systematic review and meta-analysis
Novo Nordisk, the company that makes Wegovy and Ozempic and which funded the study, said it has already filed paperwork with the Food and Drug Administration and regulators in the European Union to update Wegovys label to include that it can reduce the risk of cardiovascular events in certain patients
Myth #5: GLP1 medication is only for people with type 2 diabetes GLP-1 medications were first used as a treatment for type 2 diabetes
However, this GLP-1 medication has a longer-lasting effect on the body than the natural hormone, stimulating insulin for an extended period of time